Free Trial
NASDAQ:KRON

Kronos Bio Q1 2024 Earnings Report

Kronos Bio logo
$0.89 +0.01 (+0.91%)
Closing price 04/17/2025 04:00 PM Eastern
Extended Trading
$0.89 +0.00 (+0.23%)
As of 04/17/2025 04:29 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Kronos Bio EPS Results

Actual EPS
-$0.50
Consensus EPS
-$0.43
Beat/Miss
Missed by -$0.07
One Year Ago EPS
N/A

Kronos Bio Revenue Results

Actual Revenue
$2.52 million
Expected Revenue
$1.50 million
Beat/Miss
Beat by +$1.02 million
YoY Revenue Growth
N/A

Kronos Bio Announcement Details

Quarter
Q1 2024
Time
N/A
Conference Call Date
Wednesday, May 8, 2024
Conference Call Time
6:00PM ET

Upcoming Earnings

Kronos Bio's Q1 2025 earnings is scheduled for Thursday, May 8, 2025, with a conference call scheduled on Wednesday, May 7, 2025 at 6:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Kronos Bio Earnings Headlines

Kronos Bio Reports 2024 Financial Results
Trump and Musk fight back
Is there more to the Musk–Trump relationship than meets the eye? Jeff Brown thinks so — and he believes it has to do with a top-level initiative to build the ultimate military-grade AI system. He’s calling it the “AI Superweapon,” and he says it could soon become the center of global tech dominance. At the core of this initiative? A handful of companies tied to America’s most powerful tech platforms — and investors who act before this goes mainstream may have a rare early edge.
Kronos Bio reports Q4 EPS (43c) vs. (43c ) last year
Kronos Bio Insider Ups Holding By 36% During Year
See More Kronos Bio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Kronos Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Kronos Bio and other key companies, straight to your email.

About Kronos Bio

Kronos Bio (NASDAQ:KRON), a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutics for various cancer and other serious diseases in the United States. Its lead product candidates are KB-0742, an oral cyclin dependent kinase 9 inhibitor for the treatment of MYC-amplified solid tumors, which is in phase 2 clinical trial; and KB-9558, a core oncogenic transcription factor that drives multiple myeloma. The company was incorporated in 2017 and is headquartered in San Mateo, California.

View Kronos Bio Profile

More Earnings Resources from MarketBeat